{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:03:48Z","timestamp":1790186628589,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012224","name":"Stanley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005632","name":"Forest Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.contraception.2011.05.008","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T04:49:34Z","timestamp":1310618974000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Continuous oral levonorgestrel\/ethinyl estradiol for treating premenstrual dysphoric disorder"],"prefix":"10.1016","volume":"85","author":[{"given":"Uriel","family":"Halbreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen W.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Rapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Grubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger D.","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.05.008_bb0005","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/jwh.1.1999.8.1043","article-title":"The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France","volume":"8","author":"Hylan","year":"1999","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1016\/j.contraception.2011.05.008_bb0010","first-page":"340","article-title":"Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior","volume":"33","author":"Johnson","year":"1988","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2011.05.008_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"771","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.contraception.2011.05.008_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/jwh.2007.0417","article-title":"Burden of premenstrual dysphoric disorder on health-related quality of life","volume":"17","author":"Yang","year":"2008","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.contraception.2011.05.008_bb0025","first-page":"359","article-title":"Treatment of premenstrual disorders","volume":"51","author":"Kroll","year":"2006","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2011.05.008_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006586.pub3","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Lopez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.05.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001396.pub2","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.05.008_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.contraception.2009.03.006","article-title":"Ovarian activity and safety of a novel levonorgestrel\/ethinyl estradiol continuous oral contraceptive regimen","volume":"80","author":"Archer","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.008_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00737-005-0103-y","article-title":"Daily Record of Severity of Problems (DRSP): reliability and validity","volume":"9","author":"Endicott","year":"2006","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.contraception.2011.05.008_bb0050","first-page":"9","article-title":"The work limitations questionnaire","volume":"28","author":"Lerner","year":"2002","journal-title":"Qual Life Newsl"},{"key":"10.1016\/j.contraception.2011.05.008_bb0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1092852900016400","article-title":"Selective serotonin reuptake inhibitors and initial oral contraceptives for treatment of PMDD: effective but not enough","volume":"13","author":"Halbreich","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.contraception.2011.05.008_bb0060","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002130100718","article-title":"Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo","volume":"155","author":"Landen","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.contraception.2011.05.008_bb0065","first-page":"1219","article-title":"Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder","volume":"100","author":"Halbreich","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.008_bb0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00023210-200620070-00001","article-title":"Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome\/premenstrual dysphoric disorder?","volume":"20","author":"Halbreich","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.contraception.2011.05.008_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.npp.1301216","article-title":"Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder","volume":"32","author":"Landen","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.contraception.2011.05.008_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.contraception.2009.05.128","article-title":"Continuous, daily levonorgestrel\/ethinyl estradiol vs. 21-day, cyclic levonorgestrel\/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial","volume":"80","author":"Teichmann","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.008_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2006.07.005","article-title":"Evaluation of a continuous regimen of levonorgestrel\/ethinyl estradiol: Phase 3 study results","volume":"74","author":"Archer","year":"2006","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:17:46Z","timestamp":1790183866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0010782411002241"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.008","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous oral levonorgestrel\/ethinyl estradiol for treating premenstrual dysphoric disorder","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}